» Articles » PMID: 35454788

Stress in Metastatic Breast Cancer: To the Bone and Beyond

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Apr 23
PMID 35454788
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer (BRCA) remains as one the most prevalent cancers diagnosed in industrialised countries. Although the overall survival rate is high, the dissemination of BRCA cells to distant organs correlates with a significantly poor prognosis. This is due to the fact that there are no efficient therapeutic strategies designed to overcome the progression of the metastasis. Over the past decade, critical associations between stress and the prevalence of BRCA metastases were uncovered. Chronic stress and the concomitant sympathetic hyperactivation have been shown to accelerate the progression of the disease and the metastases incidence, specifically to the bone. In this review, we provide a summary of the sympathetic profile on BRCA. Additionally, the current knowledge regarding the sympathetic hyperactivity, and the underlying adrenergic signalling pathways, involved on the development of BRCA metastasis to distant organs (i.e., bone, lung, liver and brain) will be revealed. Since bone is a preferential target site for BRCA metastases, greater emphasis will be given to the contribution of α2- and β-adrenergic signalling in BRCA bone tropism and the occurrence of osteolytic lesions.

Citing Articles

Large Unstained Cells (LUC): A Novel Predictor of CDK4/6 Inhibitor Outcomes in HR+ HER2-Negative Metastatic Breast Cancer.

Ceylan F, Mehdiyev M, Dede D, Efil S, Tenekeci A, Bilgin B J Clin Med. 2025; 14(1.

PMID: 39797256 PMC: 11722146. DOI: 10.3390/jcm14010173.


Evaluation of lncRNAs as Potential Biomarkers for Diagnosis of Metastatic Triple-Negative Breast Cancer through Bioinformatics and Machine Learning.

Soleimani S, Pouresmaeili F, Salahshoori Far I Iran J Biotechnol. 2024; 22(3):e3853.

PMID: 39737204 PMC: 11682528. DOI: 10.30498/ijb.2024.432171.3853.


Effects of Selective and Nonselective Beta Blockers on Bone Mineral Density in Mexican Patients with Breast Cancer.

Mejia-Barradas C, Amador-Martinez A, Lara-Padilla E, Cardenas-Rodriguez N, Ignacio-Mejia I, Martinez-Lopez V Cancers (Basel). 2024; 16(16).

PMID: 39199661 PMC: 11352457. DOI: 10.3390/cancers16162891.


FTO is a major genetic link between breast cancer, obesity, and diabetes.

Gholami M Breast Cancer Res Treat. 2023; 204(1):159-169.

PMID: 38071263 DOI: 10.1007/s10549-023-07188-4.


Organ-Specificity of Breast Cancer Metastasis.

Ibragimova M, Tsyganov M, Kravtsova E, Tsydenova I, Litviakov N Int J Mol Sci. 2023; 24(21).

PMID: 37958607 PMC: 10650169. DOI: 10.3390/ijms242115625.


References
1.
McCorry L . Physiology of the autonomic nervous system. Am J Pharm Educ. 2007; 71(4):78. PMC: 1959222. DOI: 10.5688/aj710478. View

2.
Fougner C, Bergholtz H, Norum J, Sorlie T . Re-definition of claudin-low as a breast cancer phenotype. Nat Commun. 2020; 11(1):1787. PMC: 7156396. DOI: 10.1038/s41467-020-15574-5. View

3.
Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

4.
Bonnet N, Benhamou C, Malaval L, Goncalves C, Vico L, Eder V . Low dose beta-blocker prevents ovariectomy-induced bone loss in rats without affecting heart functions. J Cell Physiol. 2008; 217(3):819-27. DOI: 10.1002/jcp.21564. View

5.
Montoya A, Amaya C, Belmont A, Diab N, Trevino R, Villanueva G . Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer. Oncotarget. 2016; 8(4):6446-6460. PMC: 5351644. DOI: 10.18632/oncotarget.14119. View